Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Bhatia A, Burtness B.

Cancers (Basel). 2017 Aug 31;9(9). pii: E113. doi: 10.3390/cancers9090113. Review.

2.

Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ.

Cancer. 2017 Dec 1;123(23):4653-4662. doi: 10.1002/cncr.30920. Epub 2017 Aug 7.

PMID:
28786105
3.

First Clinical Report on Comparative Treatment and Survival Outcomes in Second Cancers after Primary Head and Neck Cancer: A Population-Based Study.

Wang X, Mauer EA, Christos P, Manzerova J, Wernicke AG, Parashar B.

Cureus. 2017 May 29;9(5):e1284. doi: 10.7759/cureus.1284.

4.

Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.

Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH.

Sci Rep. 2017 Jan 30;7:41785. doi: 10.1038/srep41785.

5.

A head and neck cancer intervention for use in survivorship clinics: a protocol for a feasibility study.

Salz T, McCabe MS, Oeffinger KC, Corcoran S, Vickers AJ, Salner AL, Dornelas E, Schnall R, Raghunathan NJ, Fortier E, Baxi SS.

Pilot Feasibility Stud. 2016 May 5;2:23. eCollection 2016.

6.
7.

Electronic Cigarette: Role in the Primary Prevention of Oral Cavity Cancer.

Franco T, Trapasso S, Puzzo L, Allegra E.

Clin Med Insights Ear Nose Throat. 2016 Oct 17;9:7-12. eCollection 2016.

8.

Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database.

Birkeland AC, Rosko AJ, Chinn SB, Prince ME, Sun GH, Spector ME.

ORL J Otorhinolaryngol Relat Spec. 2016;78(2):61-9. doi: 10.1159/000443768. Epub 2016 Feb 25.

9.

Preinvasive Endobronchial Lesions: Lung Cancer Precursors and Risk Markers?

Lam S, Szabo E.

Am J Respir Crit Care Med. 2015 Dec 15;192(12):1411-3. doi: 10.1164/rccm.201508-1668ED. No abstract available.

10.

Genome-Wide Loss of Heterozygosity and DNA Copy Number Aberration in HPV-Negative Oral Squamous Cell Carcinoma and Their Associations with Disease-Specific Survival.

Chen C, Zhang Y, Loomis MM, Upton MP, Lohavanichbutr P, Houck JR, Doody DR, Mendez E, Futran N, Schwartz SM, Wang P.

PLoS One. 2015 Aug 6;10(8):e0135074. doi: 10.1371/journal.pone.0135074. eCollection 2015.

11.

Total and partial cancer prevalence in the adult French population in 2008.

Colonna M, Mitton N, Bossard N, Belot A, Grosclaude P; French Network of Cancer Registries (FRANCIM).

BMC Cancer. 2015 Mar 19;15:153. doi: 10.1186/s12885-015-1168-2.

12.

Molecular mechanisms of ethanol-associated oro-esophageal squamous cell carcinoma.

Liu Y, Chen H, Sun Z, Chen X.

Cancer Lett. 2015 Jun 1;361(2):164-73. doi: 10.1016/j.canlet.2015.03.006. Epub 2015 Mar 9. Review.

13.

Clinical significance of early detection of esophageal cancer in patients with head and neck cancer.

Lim H, Kim DH, Jung HY, Gong EJ, Na HK, Ahn JY, Kim MY, Lee JH, Choi KS, Choi KD, Song HJ, Lee GH, Kim JH.

Gut Liver. 2015 Mar;9(2):159-65. doi: 10.5009/gnl13401.

14.

The effect of patient characteristics on second primary cancer risk in France.

Jégu J, Colonna M, Daubisse-Marliac L, Trétarre B, Ganry O, Guizard AV, Bara S, Troussard X, Bouvier V, Woronoff AS, Velten M.

BMC Cancer. 2014 Feb 15;14:94. doi: 10.1186/1471-2407-14-94.

15.

Solid tumor second primary neoplasms: who is at risk, what can we do?

Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS.

Semin Oncol. 2013 Dec;40(6):676-89. doi: 10.1053/j.seminoncol.2013.09.012. Review.

16.

Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Szabo E, Mao JT, Lam S, Reid ME, Keith RL.

Chest. 2013 May;143(5 Suppl):e40S-e60S. doi: 10.1378/chest.12-2348. Review.

17.

Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers.

Gan SJ, Dahlstrom KR, Peck BW, Caywood W, Li G, Wei Q, Zafereo ME, Sturgis EM.

Cancer. 2013 Jul 15;119(14):2593-601. doi: 10.1002/cncr.28107. Epub 2013 Apr 19.

18.

Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas.

Joseph AW, Ogawa T, Bishop JA, Lyford-Pike S, Chang X, Phelps TH, Westra WH, Pai SI.

Oral Oncol. 2013 Mar;49(3):244-8. doi: 10.1016/j.oraloncology.2012.09.009. Epub 2012 Oct 10.

19.

Incidence and prognostic significance of second primary cancers in renal cell carcinoma.

Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ.

Am J Clin Oncol. 2013 Apr;36(2):132-42. doi: 10.1097/COC.0b013e3182438ddf.

20.

Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer.

Morris LG, Sikora AG, Hayes RB, Patel SG, Ganly I.

Cancer Causes Control. 2011 May;22(5):671-9. doi: 10.1007/s10552-011-9739-2. Epub 2011 Feb 15.

Supplemental Content

Support Center